Meinolf Karthaus

8.2k total citations · 2 hit papers
186 papers, 4.3k citations indexed

About

Meinolf Karthaus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Meinolf Karthaus has authored 186 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 46 papers in Epidemiology. Recurrent topics in Meinolf Karthaus's work include Colorectal Cancer Treatments and Studies (55 papers), Neutropenia and Cancer Infections (53 papers) and Antifungal resistance and susceptibility (40 papers). Meinolf Karthaus is often cited by papers focused on Colorectal Cancer Treatments and Studies (55 papers), Neutropenia and Cancer Infections (53 papers) and Antifungal resistance and susceptibility (40 papers). Meinolf Karthaus collaborates with scholars based in Germany, United States and Italy. Meinolf Karthaus's co-authors include Oliver A. Cornely, Dieter Buchheidt, Arnold Ganser, Fernando Rivera, Lee S. Schwartzberg, Andrew J. Ullmann, Gianpiero Fasola, Jean-Luc Canon, Markus Ruhnke and J. Randolph Hecht and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Meinolf Karthaus

176 papers receiving 4.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 478 citations Lee S. Schwartzberg, Fernando Rivera et al. Journal of Clinical Oncology profile →
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

2021 161 citations Meinolf Karthaus et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meinolf Karthaus Germany	36	2.0k	1.3k	1.3k	1.1k	532	186	4.3k
Anat Gafter‐Gvili Israel	45	2.1k 1.0×	682 0.5×	1.4k 1.0×	713 0.6×	469 0.9×	218	6.6k
Gerlinde Egerer Germany	41	1.4k 0.7×	677 0.5×	927 0.7×	888 0.8×	520 1.0×	181	4.6k
Michael Green United States	42	2.3k 1.1×	1.2k 0.9×	1.6k 1.2×	322 0.3×	855 1.6×	160	5.2k
Marguerite Guiguet France	37	2.5k 1.2×	912 0.7×	2.0k 1.5×	1.2k 1.0×	1.8k 3.4×	121	6.6k
G.C. Ooi Hong Kong	30	433 0.2×	1.2k 0.9×	584 0.4×	1.0k 0.9×	324 0.6×	85	3.3k
R. A. Clift United States	32	1.7k 0.8×	287 0.2×	805 0.6×	583 0.5×	664 1.2×	59	7.7k
Finn Bo Petersen United States	33	1.6k 0.8×	901 0.7×	1.2k 0.9×	496 0.4×	286 0.5×	72	5.2k
Olaf Penack Germany	40	1.5k 0.7×	944 0.7×	1.3k 1.0×	289 0.3×	213 0.4×	136	3.9k
Amelia Langston United States	41	2.1k 1.0×	2.4k 1.8×	2.7k 2.1×	499 0.4×	332 0.6×	177	7.5k
Anna Locasciulli Italy	45	1.5k 0.7×	452 0.3×	1.4k 1.1×	307 0.3×	544 1.0×	128	5.4k

Countries citing papers authored by Meinolf Karthaus

Since Specialization

Citations

This map shows the geographic impact of Meinolf Karthaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meinolf Karthaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meinolf Karthaus more than expected).

Fields of papers citing papers by Meinolf Karthaus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meinolf Karthaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meinolf Karthaus. The network helps show where Meinolf Karthaus may publish in the future.

Co-authorship network of co-authors of Meinolf Karthaus

This figure shows the co-authorship network connecting the top 25 collaborators of Meinolf Karthaus. A scholar is included among the top collaborators of Meinolf Karthaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meinolf Karthaus. Meinolf Karthaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Moying, Nadja M. Meindl‐Beinker, Johannes Betge, et al.. (2024). Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study. Journal of Geriatric Oncology. 15(7). 101838–101838.

Klein‐Scory, Susanne, Alexander Baraniskin, Wolff Schmiegel, et al.. (2024). Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE ‐4.5 study. Molecular Oncology. 19(2). 344–356. 4 indexed citations

Wyrwicz, Lucjan, Julien Taı̈eb, Timothy Price, et al.. (2023). Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies. 12(3). 1 indexed citations

Stintzing, Sebastian, Kathrin Heinrich, David Tougeron, et al.. (2023). FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF^V600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. Journal of Clinical Oncology. 41(25). 4143–4153. 32 indexed citations

Ballhausen, Alexej, Meinolf Karthaus, Stefan Früehauf, et al.. (2023). Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. European Journal of Cancer. 190. 112955–112955. 5 indexed citations

Kurreck, Annika, Alexander Beck, Uli Fehrenbach, et al.. (2022). Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). European Journal of Cancer. 178. 37–48. 3 indexed citations

Taı̈eb, Julien, Fernando Rivera, Salvatore Siena, et al.. (2017). Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. Journal of Cancer Research and Clinical Oncology. 144(2). 321–335. 25 indexed citations

Schwartzberg, Lee S., Fernando Rivera, Meinolf Karthaus, et al.. (2014). PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. Journal of Clinical Oncology. 32(21). 2240–2247. 478 indexed citations breakdown →

Karthaus, Meinolf, Maria J. G. T. Rüping, Oliver A. Cornely, et al.. (2011). Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009. Mycoses. 54(5). 12 indexed citations

10.

Böhme, Angelika, Markus Ruhnke, Dieter Buchheidt, et al.. (2008). Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology. 88(2). 97–110. 90 indexed citations

11.

Cornely, Oliver A., Angelika Böhme, Dieter Buchheidt, et al.. (2008). Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 94(1). 113–122. 137 indexed citations

12.

Karthaus, Meinolf. (2008). Recent Epidemiology Trends of Candida Infections in Cancer and Non-Cancer Patients. 46th Annual Meeting. 1 indexed citations

13.

Rüping, Maria J. G. T., Jörg Janne Vehreschild, Chase L. Beisel, et al.. (2008). Fungiscope - the Global Database for Rare Fungal Infections. International Journal of Infectious Diseases. 12. e283–e283. 1 indexed citations

14.

Cornely, Oliver A., Andrew J. Ullmann, Meinolf Karthaus, Thomas J. Walsh, & Jo‐Anne H. van Burik. (2005). Choosing a study population for the evaluation of antifungal prophylaxis. Author's reply. Clinical Infectious Diseases. 40(11). 1699–1701. 1 indexed citations

15.

Karthaus, Meinolf, Albrecht Kretzschmar, H. Kröning, et al.. (2005). Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Annals of Oncology. 17(2). 289–296. 159 indexed citations

16.

Buchheidt, Dieter, Oliver A. Cornely, Meinolf Karthaus, et al.. (2003). Central venous catheter (CVC)-related infections in neutropenic patients. Annals of Hematology. 82(0). S149–S157. 48 indexed citations

17.

Buchheidt, Dieter, Angelika Böhme, Oliver A. Cornely, et al.. (2001). Dokumentierte Infektionen bei Neutropenie - Empfehlungen zu Diagnostik und Therapie. DMW - Deutsche Medizinische Wochenschrift. 126(39). 1085–1090. 2 indexed citations

18.

Giagounidis, Aristoteles, et al.. (1999). Serum and Plasma Parameters in Clinical Evaluation of Neutropenic Fever. PubMed. 50. 10–19. 16 indexed citations

19.

Böhme, Angelika & Meinolf Karthaus. (1999). Treatment of Systemic Fungal Infections in Patients with Hematologic Malignancies. PubMed. 50. 79–93. 2 indexed citations

20.

Böhme, Angelika, Meinolf Karthaus, & D. Hoelzer. (1999). Antifungal Prophylaxis in Neutropenic Patients with Hematologic Malignancies. PubMed. 50. 69–78. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact